366 related articles for article (PubMed ID: 11451151)
21. Preparation and characterization of a set of monoclonal antibodies to TRAIL and TRAIL receptors DR4, DR5, DcR1, and DcR2.
Liu XS; Zhu Y; Han WN; Li YN; Chen LH; Jia W; Song CJ; Liu F; Yang K; Li Q; Jin BQ
Hybrid Hybridomics; 2003 Apr; 22(2):121-5. PubMed ID: 12831538
[TBL] [Abstract][Full Text] [Related]
22. Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in established and primary glioma cell lines.
Jaganathan J; Petit JH; Lazio BE; Singh SK; Chin LS
Neurosurg Focus; 2002 Sep; 13(3):ecp1. PubMed ID: 15844877
[TBL] [Abstract][Full Text] [Related]
23. Membrane expression of DR4, DR5 and caspase-8 levels, but not Mcl-1, determine sensitivity of human myeloma cells to Apo2L/TRAIL.
Gómez-Benito M; Martinez-Lorenzo MJ; Anel A; Marzo I; Naval J
Exp Cell Res; 2007 Jul; 313(11):2378-88. PubMed ID: 17462628
[TBL] [Abstract][Full Text] [Related]
24. TRAIL/Apo-2L: mechanisms and clinical applications in cancer.
Srivastava RK
Neoplasia; 2001; 3(6):535-46. PubMed ID: 11774036
[TBL] [Abstract][Full Text] [Related]
25. TRAIL-induced eradication of primary tumour cells from multiple myeloma patient bone marrows is not related to TRAIL receptor expression or prior chemotherapy.
Lincz LF; Yeh TX; Spencer A
Leukemia; 2001 Oct; 15(10):1650-7. PubMed ID: 11587225
[TBL] [Abstract][Full Text] [Related]
26. Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs.
Ganten TM; Koschny R; Sykora J; Schulze-Bergkamen H; Büchler P; Haas TL; Schader MB; Untergasser A; Stremmel W; Walczak H
Clin Cancer Res; 2006 Apr; 12(8):2640-6. PubMed ID: 16638878
[TBL] [Abstract][Full Text] [Related]
27. Role of antiapoptotic proteins in tumor necrosis factor-related apoptosis-inducing ligand and cisplatin-augmented apoptosis.
Kim JH; Ajaz M; Lokshin A; Lee YJ
Clin Cancer Res; 2003 Aug; 9(8):3134-41. PubMed ID: 12912965
[TBL] [Abstract][Full Text] [Related]
28. Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells.
Guo F; Sigua C; Tao J; Bali P; George P; Li Y; Wittmann S; Moscinski L; Atadja P; Bhalla K
Cancer Res; 2004 Apr; 64(7):2580-9. PubMed ID: 15059915
[TBL] [Abstract][Full Text] [Related]
29. Macrophages from cancer patients: analysis of TRAIL, TRAIL receptors, and colon tumor cell apoptosis.
Herbeuval JP; Lambert C; Sabido O; Cottier M; Fournel P; Dy M; Genin C
J Natl Cancer Inst; 2003 Apr; 95(8):611-21. PubMed ID: 12697854
[TBL] [Abstract][Full Text] [Related]
30. Fas-associated death domain protein (FADD) and caspase-8 mediate up-regulation of c-Fos by Fas ligand and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) via a FLICE inhibitory protein (FLIP)-regulated pathway.
Siegmund D; Mauri D; Peters N; Juo P; Thome M; Reichwein M; Blenis J; Scheurich P; Tschopp J; Wajant H
J Biol Chem; 2001 Aug; 276(35):32585-90. PubMed ID: 11384965
[TBL] [Abstract][Full Text] [Related]
31. Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players.
Hesry V; Piquet-Pellorce C; Travert M; Donaghy L; Jégou B; Patard JJ; Guillaudeux T
Prostate; 2006 Jun; 66(9):987-95. PubMed ID: 16541419
[TBL] [Abstract][Full Text] [Related]
32. Apoptosis control by death and decoy receptors.
Ashkenazi A; Dixit VM
Curr Opin Cell Biol; 1999 Apr; 11(2):255-60. PubMed ID: 10209153
[TBL] [Abstract][Full Text] [Related]
33. Sensitization of tumor cells to Apo2 ligand/TRAIL-induced apoptosis by inhibition of casein kinase II.
Ravi R; Bedi A
Cancer Res; 2002 Aug; 62(15):4180-5. PubMed ID: 12154014
[TBL] [Abstract][Full Text] [Related]
34. Expression of tumour necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptors and sensitivity to TRAIL-induced apoptosis in primary B-cell acute lymphoblastic leukaemia cells.
Clodi K; Wimmer D; Li Y; Goodwin R; Jaeger U; Mann G; Gadner H; Younes A
Br J Haematol; 2000 Nov; 111(2):580-6. PubMed ID: 11122106
[TBL] [Abstract][Full Text] [Related]
35. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL.
Emery JG; McDonnell P; Burke MB; Deen KC; Lyn S; Silverman C; Dul E; Appelbaum ER; Eichman C; DiPrinzio R; Dodds RA; James IE; Rosenberg M; Lee JC; Young PR
J Biol Chem; 1998 Jun; 273(23):14363-7. PubMed ID: 9603945
[TBL] [Abstract][Full Text] [Related]
36. Sensitization of cells to TRAIL-induced apoptosis by decoy receptor 3.
Wu YY; Chang YC; Hsu TL; Hsieh SL; Lai MZ
J Biol Chem; 2004 Oct; 279(42):44211-8. PubMed ID: 15475369
[TBL] [Abstract][Full Text] [Related]
37. Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels.
Nimmanapalli R; Perkins CL; Orlando M; O'Bryan E; Nguyen D; Bhalla KN
Cancer Res; 2001 Jan; 61(2):759-63. PubMed ID: 11212279
[TBL] [Abstract][Full Text] [Related]
38. Mechanisms of resistance to TRAIL-induced apoptosis in cancer.
Zhang L; Fang B
Cancer Gene Ther; 2005 Mar; 12(3):228-37. PubMed ID: 15550937
[TBL] [Abstract][Full Text] [Related]
39. Apo2L/TRAIL differentially modulates the apoptotic effects of sulindac and a COX-2 selective non-steroidal anti-inflammatory agent in Bax-deficient cells.
He Q; Luo X; Huang Y; Sheikh MS
Oncogene; 2002 Sep; 21(39):6032-40. PubMed ID: 12203115
[TBL] [Abstract][Full Text] [Related]
40. Effects and expression of TRAIL and its apoptosis-promoting receptors in human pancreatic cancer.
Ozawa F; Friess H; Kleeff J; Xu ZW; Zimmermann A; Sheikh MS; Büchler MW
Cancer Lett; 2001 Feb; 163(1):71-81. PubMed ID: 11163110
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
